CLAIMS

1. A compound of the general formula **(I)**,

$$cyclo[P^1\text{-}P^2\text{-}P^3\text{-}P^4\text{-}P^5\text{-}P^6\text{-}P^7\text{-}P^8\text{-}P^9\text{-}P^{10}\text{-}P^{11}\text{-}P^{12}\text{-}T^1\text{-}T^2] \quad (I)$$

T^1 is ^{D}Pro;

T^2 is Pro; or Pro((3*S*)OH);

P^1 is Leu; Ile; Val; Nva; or Trp;

P^2 is His; Trp; or Tyr;

P^3 is Leu; Cha; *t*BuGly; Trp; Tyr; or Tyr(Me);

P^4 is Dab;

P^5 is Orn; or Lys;

P^6 is Dab; ^{D}Dab; or Pip;

P^7 is Dab;

P^8 is Trp;

P^9 is Hse; or Dab;

P^{10} is *t*BuGly; Ile; Val; Nva; Cha; Chg; or Trp;

P^{11} is Ala; Val; Alb; Ser; Asn; or Tyr; and

P^{12} is Val; Ser; or *allo*Thr;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein

T^1 is ^{D}Pro;

T^2 is Pro; or Pro((3*S*)OH);

P^1 is Leu; Ile; Val; Nva; or Trp;

P^2 is His; Trp; or Tyr;

P^3 is Leu; Cha; *t*BuGly; Trp; Tyr; or Tyr(Me);

P^4 is Dab;

P^5 is Orn; or Lys;

P^6 is Dab; ^{D}Dab; or Pip;

P^7 is Dab;

P^8 is Trp;

P^9 is Hse; or Dab;

P^{10} is *t*BuGly; Ile; Val; Nva; Cha; Chg; or Trp;

P^{11} is Ala; Val; Alb; Ser; or Asn; and

P^{12} is Val; Ser; or *allo*Thr;

or a pharmaceutically acceptable salt thereof.

3. A compound according to claims 1 or 2wherein

T^1 is ^{D}Pro;

T^2 is Pro; or Pro((3*S*)OH);

P^1 is Leu; Ile; Val; Nva; or Trp;

P^2 is His; Trp; or Tyr;

P^3 is Leu; Cha; *t*BuGly; Trp; Tyr; or Tyr(Me);

P^4 and P^7 are Dab;

P^5 is Orn; or Lys;

P^6 is ^{D}Dab; or Pip;

P^8 is Trp;

P^9 is Hse; or Dab;

P^{10} is *t*BuGly; Ile; Val; Nva; Cha; or Chg;

P^{11} is Ala; Val; Alb; Ser; Asn; or Tyr; and

P^{12} is Val; Ser; or *allo*Thr;

or a pharmaceutically acceptable salt thereof.

4. A compound according to any one of claims 1 to 3 which is selected from

cyclo(-Trp-His-Tyr-Dab-Orn-^{D}Dab-Dab-Trp-Hse-*t*BuGly-Ala-Ser-^{D}Pro-Pro-);

cyclo(-Trp-His-Tyr-Dab-Orn-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Ala-Ser-^{D}Pro-Pro-);

cyclo(-Trp-His-Cha-Dab-Orn-^{D}Dab-Dab-Trp-Dab-Nva-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Trp-His-Cha-Dab-Orn-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Val-Ser-^{D}Pro-Pro-);
cyclo(-Leu-His-Tyr-Dab-Orn-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Leu-His-Cha-Dab-Orn-Pip-Dab-Trp-Dab-*t*BuGly-Alb-Ser-^{D}Pro-Pro-);
cyclo(-Val-His-Tyr-Dab-Orn-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Nva-His-Tyr-Dab-Orn-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Trp-His-Cha-Dab-Orn-^{D}Dab-Dab-Trp-Dab-Chg-Alb-Ser-^{D}Pro-Pro-);
cyclo(-Trp-Trp-Cha-Dab-Lys-^{D}Dab-Dab-Trp-Dab-Chg-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Trp-Trp-Cha-Dab-Lys-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Trp-Trp-*t*BuGly-Dab-Orn-^{D}Dab-Dab-Trp-Dab-Cha-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Trp-Trp-Leu-Dab-Orn-^{D}Dab-Dab-Trp-Dab-Val-Ala-Val-^{D}Pro-Pro-);
cyclo(-Trp-His-Cha-Dab-Orn-Pip-Dab-Trp-Dab-*t*BuGly-Ser-Ser-^{D}Pro-Pro((3*S*)OH)-) ;
cyclo(-Trp-Trp-Cha-Dab-Orn-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Ser-Ser-^{D}Pro-Pro((3*S*)OH)-) ;
cyclo(-Trp-His-Tyr(Me)-Dab-Orn-^{D}Dab-Dab-Trp-Hse-*t*BuGly-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Leu-His-Cha-Dab-Orn-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Ala-*allo*Thr-^{D}Pro-Pro-);

or a pharmaceutically acceptable salt thereof.

5. A compound according to any one of claims 1 to 3which is selected from

cyclo(-Trp-His-Tyr-Dab-Orn-Dab-Dab-Trp-Dab-*t*BuGly-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Trp-His-Cha-Dab-Orn-Dab-Dab-Trp-Dab-*t*BuGly-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Ile-His-Tyr-Dab-Orn-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Ile-His-Tyr-Dab-Orn-^{D}Dab-Dab-Trp-Dab-Ile-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Leu-His-Tyr-Dab-Orn-Dab-Dab-Trp-Dab-Chg-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Leu-His-Tyr-Dab-Orn-^{D}Dab-Dab-Trp-Dab-Chg-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Leu-His-Trp-Dab-Orn-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Leu-His-Tyr-Dab-Lys-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Leu-Trp-Tyr-Dab-Orn-^{D}Dab-Dab-Trp-Dab-Cha-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Leu-Trp-Trp-Dab-Orn-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Leu-Trp-Tyr-Dab-Orn-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Ala-Ser-^{D}Pro-Pro-);
cyclo(-Leu-His-Tyr-Dab-Orn-^{D}Dab-Dab-Trp-Dab-Trp-Ala-Ser-^{D}Pro-Pro-);

cyclo(-Leu-His-Tyr-Dab-Orn-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Ser-Ser-^{D}Pro-Pro-);

cyclo(-Leu-Trp-Tyr-Dab-Lys-^{D}Dab-Dab-Trp-Dab-Cha-Ser-Ser-^{D}Pro-Pro-);

cyclo(-Leu-Trp-Tyr-Dab-Orn-^{D}Dab-Dab-Trp-Dab-Cha-Ser-Ser-^{D}Pro-Pro-);

cyclo(-Leu-Tyr-Tyr-Dab-Orn-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Asn-Ser-^{D}Pro-Pro-);

cyclo(-Leu-Trp-*t*BuGly-Dab-Orn-^{D}Dab-Dab-Trp-Dab-Chg-Ala-Ser-^{D}Pro-Pro-);

cyclo(-Ile-Trp-*t*BuGly-Dab-Lys-^{D}Dab-Dab-Trp-Dab-Cha-Ala-Ser-^{D}Pro-Pro-);

cyclo(-Leu-Trp-*t*BuGly-Dab-Orn-^{D}Dab-Dab-Trp-Dab-Chg-Ser-Ser-^{D}Pro-Pro-);

cyclo(-Leu-Trp-Cha-Dab-Orn-^{D}Dab-Dab-Trp-Dab-*t*BuGly-Ser-Ser-^{D}Pro-Pro-);

or a pharmaceutically acceptable salt thereof.

6. A compound according to claim 1 or 3, 5 to 6, 8 or 10 which is

cyclo(-Leu-Tyr-Tyr-Dab-Orn-^{D}Dab-Dab-Trp-Dab-tBuGly-Tyr-Ser-^{D}Pro-Pro-);

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition containing a compound or a mixture of compounds according to any one of claims 1 to 6 and at least one pharmaceutically inert carrier.

8. A pharmaceutical composition according to claim 7 in a form suitable for oral, topical, transdermal, injection, buccal, transmucosal, rectal, pulmonary or inhalation administration, especially in the form of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray, nebulizer or suppositories.

9. A compound of formula **(I)** according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, for use as a medicament.

10. The use of a compound according to any one of claims 1 to 6 for use as a pharmaceutically active substance having antibiotic activity.

11. A compound according to any one of claims 1 to 6, or a composition according claim 7 or 8, for the treatment or prevention of infections or diseases related to such infections; particularly infections related to respiratory diseases or skin or soft tissue diseases or gastrointestinal diseases or eye diseases or ear diseases or CNS diseases or bone diseases or cardiovascular diseases or genitourinary diseases, or nosocomial infections, or catheter-related and non-catheter-related infections, or urinary tract infections, or bloodstream infections; or as a disinfectants or preservatives for foodstuffs, cosmetics, medicaments and other nutrient-containing materials.

12. A process for the preparation of a compound according to any one of claims 1 to 6 which comprises

(a) coupling an appropriately functionalized solid support with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position T^1 or T^2 or P^1 to P^{12} as defined above; any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(b) removing the N-protecting group from the product obtained in step (a);

(c) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is in the position of the next element (T or P), following counterclockwise or clockwise the sequence according to general formula **(I)** in –COOH to $–NH_2$ orientation; any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(d) removing the N-protecting group from the product thus obtained;

(e) repeating steps (c) and (d) until all amino acid residues have been introduced;

(f) if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and chemically transforming the reactive group(s) thus liberated;

(g) detaching the product thus obtained from the solid support;

(h) cyclizing the product cleaved from the solid support;

(i) removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule;

(j) if desired, implementing additional chemical transformations of one or more reactive group(s) present in the molecule; and

(k) if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula **(I)** or into a different, pharmaceutically acceptable salt.

13. A compound according to any one of claims 1 to 6 for use in the treatment or prevention of infections or diseases related to such infections; particularly infections related to respiratory diseases or skin or soft tissue diseases or gastrointestinal diseases or eye diseases or ear diseases or CNS diseases or bone diseases or cardiovascular diseases or genitourinary diseases, or nosocomial infections, or catheter-related and non-catheter-related infections, or urinary tract infections, or bloodstream infections; or as a disinfectants or preservatives for foodstuffs, cosmetics, medicaments and other nutrient-containing materials.

14. A compound according to any one of claims 1 to 6 for use in the treatment of an infection, especially infections such as nosocomial infections, catheter-related and non-catheter-related infections, urinary tract infections, bloodstream infections, or a disease or disorder associated with an infection, especially diseases or disorders such as ventilator-associated pneumonia (VAP), hospital-acquired pneumonia (HAP), healthcare-associated pneumonia (HCAP), cystic fibrosis, emphysema, asthma, pneumonia, epidemic diarrhea, necrotizing enterocolitis, typhlitis, gastroenteritis, pancreatitis, keratitis, endophthalmitis, otitis, brain abscess, meningitis, encephalitis, osteochondritis, pericarditis, epididymitis, prostatitis, urethritis, surgical wounds, traumatic wounds, burns, comprising administering to a subject in need thereof a

pharmaceutically acceptable amount of a compound or pharmaceutical composition according to any one of claims 1 to 8.